Pfizer has reached a turning point.

Includes a one-time $1.35 billion Acquired In-Process R&D charge related to the in-licensing agreement with 3SBio, Inc. recorded in the third quarter of 2025 with an unfavorable impact of ...

Dr. Albert Bourla, Chairman and CEO of Pfizer: “We continued to execute with focus and discipline against our strategic priorities, including strengthening our R&D organization and driving improved ...

As pharmas like Eli Lilly and Roche bolster their biotech offerings, Pfizer is snuffing out its program designed to incubate new innovations from select companies, dubbed Pfizer Ignite. | As pharmas ...

Pfizer (PFE) reported mixed first quarter earnings Tuesday, as the company focuses on gaining investor interest in its near-term pipeline amid a volatile macro environment in the markets. Pfizer ...

Pfizer (PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results. The study met its primary endpoint, with tilrekimig showing a ...

It has been about a month since the last earnings report for Pfizer (PFE). Shares have lost about 0.6% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the ...

Second-quarter 2025 Cost of Sales(3) as a percentage of revenues increased by 0.9 percentage points compared to the prior-year quarter, driven primarily by the non-recurrence of a favorable revision ...

$2.2 billion invested in internal research and development projects, and Approximately $90 million invested in business development transactions. Returning capital directly to shareholders through ...